2018 and Radiopharmaceuticals - Diagnostic Imaging Brief

Targeted radiopharmaceuticals offer new hope for longer 'healthspans'

AuntMinnie

MARCH 15, 2024

A 2018 study from the U.S. An emerging field of precision radiopharmaceuticals brings new optimism to this mission, revolutionizing cancer care. Precision radiopharmaceuticals accurately target tumors while minimizing damage to healthy tissue. Americans today can expect to live long lives.

Radiopharmaceuticals

Radiopharmaceuticals Radiation Disease Diagnostic Imaging

Pharmacist sentenced in radiopharmaceutical criminal case

AuntMinnie

JULY 26, 2024

Evidence showed that Sheriff owned and was pharmacist in charge at Shertech, a pharmacy that provided nuclear and radiopharmaceutical drugs to medical facilities. Attorney's Office in the District of South Carolina.

Radiopharmaceuticals

Radiopharmaceuticals Disease Diagnose Medical

Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer

Imaging Technology

APRIL 10, 2024

an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, is the lead candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals. 177Lu-rhPSMA-10.1,

Radiopharmaceuticals

Radiopharmaceuticals Radiosensitivity Medical Diagnostic

First Ever Investigational 18F-CD8 PET Radiopharmaceutical Aims to Predict and Monitor Early Response to Cancer Immunotherapies

Imaging Technology

JUNE 15, 2023

The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use. Fruhwirth, G. Kneilling, M., De Vries, I. Weigelin, B.,

Radiopharmaceuticals

Radiopharmaceuticals Pharmaceutical Nuclear Medicine PET Scan

FDA approves Lutathera for some pediatric patients

AuntMinnie

MAY 1, 2024

Food and Drug Administration (FDA) has approved Novartis' Lutathera (lutetium-177 [Lu-177]) DOTATATE radiopharmaceutical for treatment of pediatric patients who are 12 years old and older with somatostatin receptor (SSTR)-positive gastroentropancreatic neuroendocrine tumors (GEP-NETs).

Radiopharmaceuticals

Radiopharmaceuticals Pharmaceutical Radiology

NorthStar Medical Technologies, LLC Appoints Frank Scholz, Ph.D., as President and Chief Executive Officer

Imaging Technology

JUNE 19, 2023

milla1cf Mon, 06/19/2023 - 19:27 June 19, 2023 — NorthStar Medical Technologies, LLC , a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the appointment of Frank Scholz, Ph.D., NorthStar’s commercialized, U.S.-based

Medical

Medical Pharmaceutical Radiopharmaceuticals Nuclear Medicine

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

Imaging Technology

APRIL 3, 2023

Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit. Ac-225 using advanced, environmentally preferable electron accelerator technology.

Medical

Medical Radiopharmaceuticals Pharmaceutical Radiation

Blue Earth Therapeutics Announces Results of Early Clinical and Preclinical Studies of Investigational 177Lu-rhPSMA-10.1 in Treatment of Prostate Cancer

Imaging Technology

JUNE 29, 2023

milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1

Clinic

Clinic Nuclear Medicine Radiopharmaceuticals Radiation

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

Imaging Technology

MAY 2, 2023

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 Gauden , D.Phil., 18F-rhPSMA-7.3

Diagnostic

Diagnostic Radiopharmaceuticals Imaging Radiation

Will new CPT codes spark utilization of quantitative MRI?

AuntMinnie

JANUARY 30, 2024

In 2018, Alosco received nearly $800,000 from the National Institutes of Health's National Institute of Neurological Disorders and Stroke for the research. A widely used class of radiopharmaceuticals in the study of the neuroinflammatory response targets the translocator protein (TSPO), according to the researchers.

MRI

MRI Radiopharmaceuticals Disease Imaging

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. POSLUMA was developed to assist physicians in the detection and localization of prostate cancer.

Diagnostic

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging

Meet the Minnies 2024 finalists

AuntMinnie

OCTOBER 25, 2024

In 2018 he received an endowed professorship from the university. Beyder played a key role in launching the radiopharmaceutical therapy (RPT) comprehensive center of excellence at WU, BJH, and Siteman Cancer Center last year.

Nuclear Medicine

Nuclear Medicine Education Radiation Science Radiology Technologist

Blue Earth Diagnostics Announces Addition of POSLUMA (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer

Imaging Technology

JULY 28, 2023

POSLUMA represents a new class of high-affinity PSMA-targeted PET radiopharmaceuticals based on novel radiohybrid technology and is labeled with the radioisotope 18F to provide readily available patient access and leverage the high image quality of 18F-labeled PSMA PET imaging to facilitate effective detection of disease.

Diagnostic

Diagnostic Clinic Radiopharmaceuticals Radiation

Generative AI, radiologist shortages feature in 2024 Minnies

AuntMinnie

NOVEMBER 12, 2024

In 2018, Fishman received an endowed professorship from Johns Hopkins. Beyder played a key role in launching the radiopharmaceutical therapy (RPT) comprehensive center of excellence at WU, BJH, and Siteman Cancer Center last year. from Ukraine.

Radiologist

Radiologist Education Clinic Radiology

Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

Imaging Technology

OCTOBER 5, 2023

Nationally recognized clinical oncology guidelines for prostate cancer now include POSLUMA, alongside and for all the same categories as the other currently FDA-approved PSMA PET radiopharmaceuticals.” PET in Men with Newly Diagnosed High-risk Prostate Cancer and Negative Conventional Imaging, ” by Phillip H.

Diagnose

Diagnose Diagnostic Radiation Disease

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine

Nuclear Medicine Radiopharmaceuticals Radiation Health Science

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine

Nuclear Medicine Radiopharmaceuticals Radiation Health Science

Diagnostic Imaging Brief

Targeted radiopharmaceuticals offer new hope for longer 'healthspans'

Pharmacist sentenced in radiopharmaceutical criminal case

Trending Sources

Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer

First Ever Investigational 18F-CD8 PET Radiopharmaceutical Aims to Predict and Monitor Early Response to Cancer Immunotherapies

FDA approves Lutathera for some pediatric patients

NorthStar Medical Technologies, LLC Appoints Frank Scholz, Ph.D., as President and Chief Executive Officer

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

Blue Earth Therapeutics Announces Results of Early Clinical and Preclinical Studies of Investigational 177Lu-rhPSMA-10.1 in Treatment of Prostate Cancer

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

Will new CPT codes spark utilization of quantitative MRI?

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

Meet the Minnies 2024 finalists

Blue Earth Diagnostics Announces Addition of POSLUMA (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer

Generative AI, radiologist shortages feature in 2024 Minnies

Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

The rise of theranostics: Part 1 -- Gaining momentum

The rise of theranostics: Part 1 -- Gaining momentum

Stay Connected